هذه هي أحدث مجموعة مختارة من المنشورات وبراءات الاختراع العالمية باللغة الإنجليزية في مجال التكنولوجيا الحيوية وCRISPR، بين العديد من المجلات العلمية على الإنترنت، مصنفة ومركزة على CRISPR، وتحرير الجينات، وGRNA، وتسلسل PAM، وانشقاق الحمض النووي، وبروتين Cas9، وتحرير الجينوم، وإدخال الجينات، وضرب الجينات.
Class 2, type v crispr systems
Patent published on the 2026-06-11 in WO under Ref WO2026122844 by METAGENOMI THERAPEUTICS INC [US] (Brown Christopher [us], Goltsman Daniela S A [us], Matheus Carnevali Paula B [us], Hackney Margaret [us], Temoche-diaz Morayma [us], Thomas Brian C [us], Luong Thao [us], Butterfield Cristina Noel [us], Senger Kate [us], Devoto Audra [us], Alexander Lisa )
Abstract: Described herein are engineered endonuclease systems for modifying target genes. In certain embodiments, are engineered nuclease systems, comprising: a) an engineered endonuclease having at least 70% sequence identity to any one of SEQ ID NOs: 215-225 and 3471-3684; and b)an engineered guide polynucleotide configured to form a complex with the endonuclease and to hybridize to a target nucleic acid sequence within a valosin-containing protein (VCP) gene, the engineered guide polynucleotide compri[...]
Our summary: The content describes engineered endonuclease systems for gene modification. It details the components, including engineered endonucleases with high sequence identity. Additionally, it specifies engineered guide polynucleotides designed to hybridize with target sequences in the VCP gene.
CRISPR, endonuclease, gene modification, guide polynucleotide
Patent
Method for enhancing plant transformation efficiency by using agrobacterium carrying virg mutant gene and nahg gene
Patent published on the 2026-06-11 in US under Ref US20260159848 by NULLA BIO INC [KR] (Jeon Eun-young [kr], Jeong Jin-hee [kr])
Abstract: [0000] A method for enhancing transformation efficiency of a plant includes transforming a plant cell with a bacteria of the genus Agrobacterium carrying virGgene and NahG (salicylate hydroxylase) gene. The method is based on the discovery that introducing both a constitutively active virG mutant gene (virG) and a salicylic acid-degrading gene (NahG) into an Agrobacterium strain synergistically increases its ability to deliver a target gene into a plant cell. The provided strains can be used to [...]
Our summary: The method enhances plant transformation efficiency by using Agrobacterium with a virG mutant and NahG gene. This approach improves gene delivery into plant cells. It is applicable to various plant species, including those that are typically difficult to transform.
Agrobacterium, plant transformation, virG gene, NahG gene
Patent
Method for producing genome-edited hemp plant having increased cbd content and decreased thc content by csthcas gene editing, and genome-edited hemp p
Patent published on the 2026-06-04 in WO under Ref WO2026117122 by HOPS BIOSCIENCES INC [KR] (Lee Jeong Hwan [kr], Kim Young Cheon [kr])
Abstract: The present invention relates to: a method for producing a genome-edited hemp plant having an increased cannabidiol (CBD) content and a decreased delta-9-tetrahydrocannabinol (THC) content by editing a hemp-derived cannabis sativa delta-9-tetrahydrocannabinolic acid synthase (CsTHCAS) gene; and a genome-edited hemp plant having an increased CBD content and a decreased THC content produced by said method. The production method according to the present invention increases the content of CBD, which[...]
Our summary: This invention describes a method for creating genome-edited hemp plants with higher CBD and lower THC levels. It utilizes the CsTHCAS gene editing technique. The resulting hemp varieties can be beneficial for medicinal applications.
gene editing, hemp plant, CBD content, THC content
Patent
Engineered exosomes and methods for producing the same
Patent published on the 2026-05-21 in US under Ref US20260137808 by UNIV KENTUCKY RES FOUND [US] (Tong Sheng [us], Yang Xiaoyue [us])
Abstract: [0000] Methods for producing an engineered exosome (eEXO) that make use of one or more magnetic nanoparticles (MNPs) complexed with a therapeutic payload are provided. The MNP-therapeutic payload complex is loaded into an endosome of a producer cell. The enriched endosome containing the MNP-therapeutic payload complex is extracted from the producer cell and extruded to produce the eEXO. Loading of the MNP-therapeutic payload complex and extraction of the enriched endosome can be facilitated by t[...]
Our summary: Methods for producing engineered exosomes involve loading magnetic nanoparticles with a therapeutic payload into the endosome of a producer cell. The enriched endosome is extracted and extruded to create the engineered exosomes. CRISPR ribonucleoprotein can serve as the therapeutic payload for gene editing applications.
engineered exosomes, magnetic nanoparticles, therapeutic payload, CRISPR
Patent
Transmembrane receptor gene editing
Patent published on the 2026-04-23 in WO under Ref WO2026085500 by ORTHOBIO THERAPEUTICS INC [US] (Millett Peter J [us], Russell Iain Alasdair [gb], Allen Matthew J [gb], Gentsch George [gb])
Abstract: Provided herein are compositions and methods for ablating intracellular signaling through specific cell surface receptors as means of treatment for various conditions of a pro-inflammatory character. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint. In some aspects, the compositions and method are for treating or preventing localized nociception, inflammation[...]
Our summary: This content discusses methods for editing transmembrane receptor genes to inhibit intracellular signaling. The approaches aim to treat pro-inflammatory conditions, particularly osteoarthritis and related disorders. Additionally, the methods target localized nociception and inflammation associated with back or spine issues.
gene editing, transmembrane receptors, inflammation treatment, osteoarthritis
Patent
Use of inhibitors or modulators of artemis in gene editing
Patent published on the 2026-04-23 in WO under Ref WO2026083309 by ASTRAZENECA AB [SE] (Dacquay Louis [se], Choong Oi Kuan [se], Akrap Nina [se], Peterka Martin [se], Maresca Marcello [se])
Abstract: The present disclosure provides modulators or inhibitors of Artemis and their uses for promoting sequence integration into a target genomic locus in a cell by non-homologous end joining-mediated prime editing.[...]
Our summary: The disclosure presents modulators or inhibitors of Artemis. These compounds promote sequence integration into target genomic loci. The method utilizes non-homologous end joining-mediated prime editing.
Artemis, gene editing, inhibitors, prime editing
Patent
Re-evaluating the site-directed nuclease classification as a regulatory trigger for genome-edited plant products
Published on 2026-03-05 by Osman Mewett, John McMurdy, Lieselot Bertho, Ana Atanassova, Naomi Stevens, Scott Huber, Maria Fedorova, Kevin Diehl, Kevin Tianmeng Zhao @NATURE
Abstract: Nature Biotechnology, Published online: 05 March 2026; doi:10.1038/s41587-026-03028-0Site-directed nuclease (SDN) classification into SDN-1, SDN-2 and SDN-3 outcomes is used for regulating genome-edited plant products in some countries. This reductive categorization system fails to cover the breadth of genome editing technologies developed over the past decade and their rapidly approaching commercial use. Here, we argue that, in the context of plant breeding, regulations should focus on the char[...]
Our summary: The current classification of site-directed nucleases (SDNs) is inadequate for regulating genome-edited plants. A shift towards an outcome-focused regulatory approach is proposed to enhance oversight and efficiency. This change aims to address challenges in crop improvement related to climate change and pest resistance.
genome editing, site-directed nucleases, regulatory framework, plant breeding
Publication
Ethical and Clinical Best Practices for Genome Editing Applications
Published on 2026-02-02 by Mara Ortiz-Bueno, Federica Zinghirino, Pilar Puig Serra, Kyriaki Paschoudi, Lluis Montoliu, Erden Atilla, Yonglun Luo, Alessia Cavazza, Carsten W. Lederer, Karim Benabdellah @MDPI
Abstract: Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders. Several technologies support these advances, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, of which the latter has emerged as the most accessible, versatile, and popular. While GE holds great promise, i[...]
Our summary: Genome editing technologies enable precise DNA modifications for medical treatments. Ethical and regulatory considerations are crucial for safe clinical applications. Regulatory agencies provide guidance on safety, consent, and compliance in genome editing practices.
Genome Editing, Ethical Standards, Regulatory Compliance, Clinical Applications
Publication











